Rhythm Pharmaceuticals Stock Forecast
NASDAQ: RYTMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RYTM analyst consensus
Consensus (19 analysts)
strong_buy
Avg. price target
$140.12+24.71%
- Strong buy 5
- Buy 12
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 19 Wall Street analysts covering Rhythm Pharmaceuticals (2026-11-17), 17 rate the stock a buy or strong buy, 2 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $140.12, with a high estimate of $168.00 and a low estimate of $112.00. The average target implies upside of 24.7% from the current price of $112.36.
The spread between the highest and lowest targets is 50.0%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for RYTM.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 5 | 26% |
| Buy | 12 | 63% |
| Hold | 2 | 11% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-11-17.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $112.00 | -0.32% |
| Average target | $140.12 | +24.71% |
| High target | $168.00 | +49.52% |